Market Overview

UPDATE: Paradigm Capital Lowers PT to $67 on Valeant Pharmaceuticals on Raising Interest Cost

Share:
Related VRX
Benzinga's M&A Chatter for Thursday August 20, 2015
Valeant CEO Reveals Plans For Female Libido Enhancement Medication Addyi
Acelity Files To Float, But Is It Secretly Seeking A Buyer? (Seeking Alpha)

Paradigm Capital reiterated its Buy rating on Valeant Pharmaceuticals (NYSE: VRX) but lowered its price target from $70 to $67 ahead of the quarterly earnings release.

Paradigm Capital commented, "We continue to hold a positive view toward Valeant's unique approach to running a specialty pharmaceutical company, which we believe sets it apart from its peers. That said, the debt raised recently to pay for the Medicis acquisition leads to a material increase in interest payments, which dilutes the company's earnings power. We are lowering our price target to $67.00 (from $70.00) to account for these interest payments."

Valeant Pharmaceuticals closed at $54.62 on Tuesday.

Latest Ratings for VRX

DateFirmActionFromTo
Jul 2015Morgan StanleyMaintainsOverweight
Jul 2015RBC CapitalMaintainsOutperform
Jul 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Paradigm CapitalAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters